Capstone Holding Corp. lowers convertible note conversion price to $1.00
NEW YORK - Goldman Sachs & Co (NYSE:GS). LLC has reported a stake in biopharmaceutical company Mural Oncology PLC, according to a regulatory filing with the Irish Takeover Panel. The disclosure, made public on May 16, 2025, indicates that the investment bank has both long and short positions in the company’s USD 0.01 ordinary shares.
As of the last dealing date on May 15, 2025, Goldman Sachs held 180,358 shares long, representing approximately 1.04% of Mural Oncology’s issued share capital, and 183,665 shares short, equating to around 1.06%. The bank also reported a purchase of 12 Mural Oncology shares at a price of $2.49 each.
The filing did not reveal any interests or short positions in other classes of relevant securities of Mural Oncology. Additionally, there were no options or derivative transactions reported other than a purchased swap with a number of 1 relevant security at an exercise price of $0.0000, expiring on July 8, 2025.
Goldman Sachs confirmed that there are no agreements, arrangements, or understandings in place relating to the voting rights of any relevant securities under any options or derivatives referenced in the disclosure. The contact names provided for the disclosure were Papa Lette and Andrzej Szyszka, with telephone numbers for further inquiries.
This disclosure is mandated under Rule 8.3 of the Irish Takeover Panel Act, 1997, Takeover Rules, 2013, which requires parties with interests in relevant securities representing 1% or more to report their dealings. The information is based on a press release statement and is intended to provide transparency in the dealings of significant shareholders of companies subject to takeover rules.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.